Print  |  Close

Clinical Trial Search Results

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.

All Clinical Trials

Records 1 - 668 of 668
1.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05186753
Protocol IDs
Treatment Sites (1)
4.
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Neuroblastoma
NCI ID
NCT04239092
Protocol IDs
1902
NCI-2020-04584
5.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCI ID
NCT05086692
Protocol IDs
Treatment Sites (1)
6.
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT05933577
Protocol IDs
Treatment Sites (1)
10.
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Cancer Type
Leukemia
NCI ID
NCT05006716
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
11.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Cancer Type
Lung Cancer
NCI ID
NCT05211895
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
12.
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT02954094
Protocol IDs
13.
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Cancer Type
Solid Tumor
NCI ID
NCT06208878
Protocol IDs
Treatment Sites (1)
14.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05201781
Protocol IDs
Treatment Sites (1)
15.
16.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
18.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
21.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
Treatment Sites (1)
22.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT06270706
Protocol IDs
Treatment Sites (1)
23.
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Cancer Type
Leukemia
NCI ID
NCT05918692
Protocol IDs
Treatment Sites (1)
24.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05150691
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
27.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05972720
Protocol IDs
Treatment Sites (1)
31.
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT06084884
Protocol IDs
Treatment Sites (1)
35.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT02339571
Protocol IDs
Treatment Sites (5)
37.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06112379
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
47.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04409301
Protocol IDs
Treatment Sites (2)
48.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05482971
Protocol IDs
Treatment Sites (1)
60.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
61.
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Cancer Type
Germ Cell Tumor, Gestational trophoblastic disease, Testicular Cancer, Unknown Primary
NCI ID
NCT04684368
Protocol IDs
ACNS2021
ACNS2021
NCI-2020-13175
62.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCI ID
NCT06120075
Protocol IDs
Treatment Sites (1)
63.
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCI ID
NCT05548296
Protocol IDs
Treatment Sites (2)
64.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05651932
Protocol IDs
Treatment Sites (1)
65.
A Study of ASP1012 in Adults With Solid Tumors
Cancer Type
Melanoma, Stomach/ Gastric Cancer
NCI ID
NCT06171178
Protocol IDs
Treatment Sites (1)
66.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCI ID
NCT06072781
Protocol IDs
Treatment Sites (1)
68.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03571568
Protocol IDs
Treatment Sites (1)
69.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCI ID
NCT04322318
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
70.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
71.
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Cancer Type
Unknown Primary
NCI ID
NCT05643638
Protocol IDs
Treatment Sites (1)
72.
A Study of Daratumumab
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05438043
Protocol IDs
Treatment Sites (1)
73.
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT05250973
Protocol IDs
Treatment Sites (1)
76.
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Solid Tumor
NCI ID
NCT05726864
Protocol IDs
Treatment Sites (1)
77.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT06064877
Protocol IDs
Treatment Sites (1)
78.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
79.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05514054
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
82.
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT05249101
Protocol IDs
83.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
84.
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05614739
Protocol IDs
Treatment Sites (1)
86.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCI ID
NCT06238479
Protocol IDs
Treatment Sites (1)
87.
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05293496
Protocol IDs
Treatment Sites (1)
88.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
89.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia
NCI ID
NCT05131022
Protocol IDs
Treatment Sites (1)
91.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05787587
Protocol IDs
Treatment Sites (1)
92.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Cancer Type
Lymphoma, Neuroblastoma
NCI ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
93.
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer Type
Head and Neck Cancer
NCI ID
NCT04974398
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
95.
A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia
Cancer Type
Leukemia
NCI ID
NCT05761171
Protocol IDs
AALL2121
AALL2121
NCI-2023-00503
97.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT05487170
Protocol IDs
Treatment Sites (1)
98.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
Treatment Sites (1)
100.
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Cancer Type
Unknown Primary
NCI ID
NCT04683003
Protocol IDs
Treatment Sites (1)
101.
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04634552
Protocol IDs
Treatment Sites (1)
104.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
106.
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05490446
Protocol IDs
Treatment Sites (1)
107.
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04586426
Protocol IDs
Treatment Sites (1)
108.
A Study of the Drug Selinexor with Radiation Therapy in Patients with Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT05099003
Protocol IDs
ACNS1821
ACNS1821
NCI-2021-11337
109.
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03871257
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
110.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT04166409
Protocol IDs
ACNS1833
ACNS1833
NCI-2019-07600
111.
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05473910
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
112.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCI ID
NCT02817633
Protocol IDs
Treatment Sites (1)
115.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05377996
Protocol IDs
Treatment Sites (1)
116.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Cancer Type
Lung Cancer, Pancreatic Cancer
NCI ID
NCT02912949
Protocol IDs
MCLA-128-CL01
NCI-2019-06025
2014-003277-42
117.
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT04814108
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
118.
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioma with Elevated Mutational Burden
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04145115
Protocol IDs
A071702
A071702
NCI-2019-07242
119.
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05907304
Protocol IDs
Treatment Sites (1)
120.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
122.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04546399
Protocol IDs
Treatment Sites (1)
123.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT04994132
Protocol IDs
Treatment Sites (1)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
126.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT05675410
Protocol IDs
AHOD2131
AHOD2131
NCI-2022-10845
128.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
129.
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT04251052
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
137.
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04970901
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
140.
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Cancer Type
Multiple Myeloma
NCI ID
NCT06271252
Protocol IDs
Treatment Sites (1)
141.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCI ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
142.
A Study to Examine Computerized Training to Improve Concentration, Learning New Things, and Remembering in Stage I-III Breast Cancer Survivors
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05896189
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
143.
145.
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT03914625
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
147.
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04946864
Protocol IDs
APG2575XU103
NCI-2021-11630
149.
A Study to Learn More About the Health of Persons with Down Syndrome After Treatment for Acute Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05702645
Protocol IDs
ALTE22C1
ALTE22C1
ALTE22C1
NCI-2022-09410
150.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Cancer Type
Unknown Primary
NCI ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
152.
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Cancer Type
Lung Cancer
NCI ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
153.
A Study with Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT05828069
Protocol IDs
ANHL2121
ANHL2121
NCI-2022-06282
NCT05287295
154.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03970447
Protocol IDs
Treatment Sites (1)
155.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Stomach/ Gastric Cancer
NCI ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
156.
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06091254
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
157.
159.
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04673617
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
160.
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
161.
162.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
163.
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT02582697
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
164.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05653271
Protocol IDs
Treatment Sites (1)
165.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT03067181
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
166.
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Cancer Type
Head and Neck Cancer
NCI ID
NCT05814666
Protocol IDs
Treatment Sites (1)
167.
ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03698552
Protocol IDs
Treatment Sites (1)
169.
Additional Support Program via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04379570
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
170.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Solid Tumor
NCI ID
NCT03391778
Protocol IDs
Treatment Sites (1)
171.
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04849910
Protocol IDs
Treatment Sites (1)
172.
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Cancer Type
Leukemia
NCI ID
NCT05487651
Protocol IDs
Treatment Sites (1)
173.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05952557
Protocol IDs
Treatment Sites (1)
176.
An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type
Cancer Control
NCI ID
NCT04462302
Protocol IDs
Treatment Sites (1)
177.
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
180.
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT05364086
Protocol IDs
Treatment Sites (21)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
181.
An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT06073431
Protocol IDs
Treatment Sites (2)
183.
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05011058
Protocol IDs
Treatment Sites (1)
185.
ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04662580
Protocol IDs
Treatment Sites (1)
187.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Cancer Type
Leukemia
NCI ID
NCT05384587
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
188.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed At Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
189.
Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT06254911
Protocol IDs
Treatment Sites (2)
191.
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03233854
Protocol IDs
Treatment Sites (1)
192.
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03564587
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
193.
AYA-RISE for the Improvement of Cancer Risk Communication and Decision-Making in Adolescents and Young Adults with Cancer Risk Syndromes
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT04323774
Protocol IDs
20-003
NCI-2020-03811
194.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type
Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT06346392
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
195.
Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence
Cancer Type
Leukemia
NCI ID
NCT05587582
Protocol IDs
I 1832021
NCI-2021-09311
196.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
197.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT05387915
Protocol IDs
Treatment Sites (2)
198.
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (16)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
199.
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCI ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
200.
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT03114865
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
201.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCI ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
203.
204.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT01896999
Protocol IDs
Treatment Sites (1)
205.
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type
Solid Tumor
NCI ID
NCT03996265
Protocol IDs
Treatment Sites (3)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
206.
Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT03611595
Protocol IDs
171971
NCI-2018-02497
207.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
208.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
209.
Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04798339
Protocol IDs
Treatment Sites (1)
210.
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01499394
Protocol IDs
Treatment Sites (1)
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
211.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCI ID
NCT02445222
Protocol IDs
Treatment Sites (1)
212.
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Cancer Type
Lymphoma, Sarcoma
NCI ID
NCT04870944
Protocol IDs
PEPN2111
PEPN2111
NCI-2021-03150
213.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
214.
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCI ID
NCT05366881
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
215.
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT06328699
Protocol IDs
Treatment Sites (1)
216.
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT05304585
Protocol IDs
ARST2032
ARST2032
NCI-2022-01012
217.
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Cancer Type
Lung Cancer
NCI ID
NCT05271292
Protocol IDs
Treatment Sites (1)
218.
Childhood Cancer Predisposition Study
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT04511806
Protocol IDs
CHOA4972-20
NCI-2020-01621
STUDY00000109
219.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
NCI ID
NCT01120353
Protocol IDs
Treatment Sites (2)
221.
CIBMTR Research Database
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01166009
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
222.
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery
Cancer Type
Brain Tumor, Liver Cancer / Hepatoblastoma
NCI ID
NCT03533582
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
223.
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Cancer Type
Unknown Primary
NCI ID
NCT06517641
Protocol IDs
Treatment Sites (1)
225.
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05143996
Protocol IDs
Treatment Sites (1)
226.
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCI ID
NCT06059391
Protocol IDs
Treatment Sites (1)
227.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT05334069
Protocol IDs
Treatment Sites (1)
228.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Solid Tumor
NCI ID
NCT02474160
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
229.
Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04242095
Protocol IDs
A151804
A151804
NCI-2019-07113
230.
231.
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05721755
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
232.
Communication Issues in Patient and Provider Discussions of Immunotherapy
Cancer Type
Solid Tumor
NCI ID
NCT05873608
Protocol IDs
Treatment Sites (2)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
233.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05050162
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
234.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT05642572
Protocol IDs
Treatment Sites (3)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
239.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCI ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
240.
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT04333537
Protocol IDs
NRG-HN006
NRG-HN006
NCI-2020-01542
242.
Comparing the Addition of Radiation either before or after Surgery for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT05438212
Protocol IDs
Treatment Sites (1)
244.
Comparing Two Methods to Follow Patients with Pancreatic Cysts
Cancer Type
Unknown Primary
NCI ID
NCT04239573
Protocol IDs
EA2185
EA2185
ECOG-ACRIN-EA2185
NCI-2019-04790
245.
Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type
Gallbladder Cancer, Unknown Primary
NCI ID
NCT04559139
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
248.
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT01688011
Protocol IDs
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
249.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT04637763
Protocol IDs
Treatment Sites (1)
250.
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT06128044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
252.
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT03904862
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
253.
Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT03919071
Protocol IDs
Treatment Sites (1)
254.
DALY II USA/ MB-CART2019.1 for DLBCL
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04792489
Protocol IDs
Treatment Sites (1)
255.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04352205
Protocol IDs
Treatment Sites (1)
259.
Decision Support Training for Family Caregivers of Patients with Advanced Cancer, CASCADE Factorial Study
Cancer Type
Breast Cancer, Head and Neck Cancer, Lung Cancer, Melanoma
NCI ID
NCT04803604
Protocol IDs
Treatment Sites (1)
260.
DECOY20 Study in Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCI ID
NCT05651022
Protocol IDs
Treatment Sites (1)
262.
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06216574
Protocol IDs
WF-2202
WF-2202
WF-2202
NCI-2023-06866
263.
Digital Meditation for Postoperative Pain Control after Abdominal Surgery for Cancer
Cancer Type
Solid Tumor
NCI ID
NCT05346692
Protocol IDs
EU5450-21
NCI-2022-01830
STUDY00003299
264.
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03233191
Protocol IDs
Treatment Sites (3)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
265.
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT06172296
Protocol IDs
ANBL2131
ANBL2131
NCI-2023-08530
266.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04567420
Protocol IDs
DARE
NCI-2021-03770
269.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03399799
Protocol IDs
CR108404
NCI-2018-00367
64407564MMY1001
2017-002400-26
272.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05552469
Protocol IDs
Treatment Sites (1)
273.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCI ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
275.
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Cancer Type
Lung Cancer
NCI ID
NCT03833154
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
276.
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04652960
Protocol IDs
Treatment Sites (1)
277.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
278.
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Cancer Type
Melanoma
NCI ID
NCT04688658
Protocol IDs
HCC 20-155
NCI-2021-13070
280.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03322891
Protocol IDs
Treatment Sites (4)
283.
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03485209
Protocol IDs
Treatment Sites (1)
285.
EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCI ID
NCT03935282
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
286.
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type
Unknown Primary
NCI ID
NCT04620239
Protocol IDs
Treatment Sites (1)
289.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCI ID
NCT03213652
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
291.
292.
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type
Solid Tumor
NCI ID
NCT03997370
Protocol IDs
Treatment Sites (1)
293.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT03501576
Protocol IDs
295.
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT04996706
Protocol IDs
Treatment Sites (1)
296.
Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type
Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer
NCI ID
NCT05394428
Protocol IDs
Treatment Sites (1)
297.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03328104
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
299.
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
Cancer Type
Graft Versus Host Disease
NCI ID
NCT05544032
Protocol IDs
Treatment Sites (1)
301.
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT05776134
Protocol IDs
Treatment Sites (1)
302.
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Cancer Type
Bone Tumor, Breast Cancer, Lung Cancer, Prostate Cancer
NCI ID
NCT00882609
Protocol IDs
Treatment Sites (1)
303.
Faith-Based African American Cancer Survivorship Storytelling
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03082612
Protocol IDs
Treatment Sites (1)
304.
Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT02759549
Protocol IDs
Treatment Sites (1)
305.
Fiber-Rich Foods for the Treatment of Obesity and Prevention of Colon Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT04780477
Protocol IDs
Treatment Sites (1)
307.
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT00785525
Protocol IDs
Treatment Sites (1)
308.
Financial Difficulty in Patients with Blood Cancer
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05212233
Protocol IDs
Treatment Sites (1)
309.
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Cancer Type
Leukemia
NCI ID
NCT04928599
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
310.
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04960787
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
312.
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05103046
Protocol IDs
Treatment Sites (1)
313.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCI ID
NCT03401385
Protocol IDs
Treatment Sites (1)
316.
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma
NCI ID
NCT04824794
Protocol IDs
Treatment Sites (1)
317.
Gene Expression in Blood Samples from High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
319.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT03994796
Protocol IDs
Treatment Sites (1)
320.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
321.
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02194738
Protocol IDs
Treatment Sites (27)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Gwinnett Medical Center
Lawrenceville
404-851-2340
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
322.
Head and Neck cancERs International cOviD-19 collabOraTion
Cancer Type
COVID-19, Head and Neck Cancer, Thyroid Cancer
NCI ID
NCT04632173
Protocol IDs
HERODOTUS
NCI-2021-11878
323.
324.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05659381
Protocol IDs
Treatment Sites (1)
325.
HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03260491
Protocol IDs
Treatment Sites (1)
327.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Cancer Type
Cancer-Related Syndrome, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04904588
Protocol IDs
ACCESS
NCI-2021-06605
329.
HPVIQ-PedOnc Intervention in Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04469569
Protocol IDs
Treatment Sites (1)
330.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02530034
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
331.
Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04278118
Protocol IDs
Treatment Sites (1)
332.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04776395
Protocol IDs
WINSHIP5157-20
NCI-2020-08351
333.
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Cancer Type
Melanoma
NCI ID
NCT05987332
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
336.
Imaging and Blood Biomarker Evaluation of Engraftment after Allogeneic Hematopoietic Stem Cell Transplant, REVEAL Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT03541889
Protocol IDs
OUHSC4891-19
NCI-2020-13763
337.
338.
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type
Solid Tumor
NCI ID
NCT04871542
Protocol IDs
Treatment Sites (4)
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
339.
Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer
Cancer Type
Unknown Primary
NCI ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
340.
Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Sarcoma
NCI ID
NCT04416568
Protocol IDs
20-041
NCI-2020-04573
342.
Implementation and Effectiveness of HN-STAR in Managing the Health of Head and Neck Squamous Cell Cancer Survivors
Cancer Type
Head and Neck Cancer
NCI ID
NCT04208490
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
343.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type
Solid Tumor
NCI ID
NCT05108298
Protocol IDs
Treatment Sites (1)
345.
Informational Meetings for Planning and Coordinating Treatment, The IMPACT Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Sarcoma, Solid Tumor
NCI ID
NCT04330833
Protocol IDs
IUSCC-0705
NCI-2021-01462
346.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
348.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type
Leukemia, Testicular Cancer
NCI ID
NCT03959085
Protocol IDs
Treatment Sites (3)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
349.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02981628
Protocol IDs
Treatment Sites (1)
350.
Intensity-Modulated Proton Therapy in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04342429
Protocol IDs
RAD4649-19
NCI-2019-02577
352.
International CIPN Assessment and Validation Study (ICAVS)
Cancer Type
NCI ID
NCT04633655
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
353.
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type
Prostate Cancer
NCI ID
NCT03151629
Protocol IDs
Treatment Sites (1)
354.
Intraoperative Radiation Therapy in Treating Patients with Breast Cancer Undergoing Breast-Conserving Surgery
Cancer Type
Breast Cancer
NCI ID
NCT01570998
Protocol IDs
Treatment Sites (1)
357.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
360.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCI ID
NCT05047536
Protocol IDs
Treatment Sites (2)
361.
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Cancer Type
Bladder Cancer
NCI ID
NCT04752722
Protocol IDs
EG-70-101
NCI-2021-12422
363.
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04393350
Protocol IDs
Winship4955-20
NCI-2020-01064
364.
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT05103904
Protocol IDs
Winship5381-21
NCI-2021-07757
STUDY00003060
366.
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT04095364
Protocol IDs
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
367.
368.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Cancer Type
Unknown Primary
NCI ID
NCT03435796
Protocol IDs
GC-LTFU-001
NCI-2018-00957
U1111-1206-8250
2017-001465-24
369.
Long-term Follow-up Study of Allogeneic Gamma Delta (?d) CAR T Cells
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT04911478
Protocol IDs
Treatment Sites (1)
371.
Losartan and Sunitinib for the Treatment of Relapsed or Refractory Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT03900793
Protocol IDs
18-2740
NCI-2019-06119
18-2740.cc
373.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03858205
Protocol IDs
Treatment Sites (1)
374.
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05900986
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
375.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT03053193
Protocol IDs
Treatment Sites (6)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
376.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type
Melanoma
NCI ID
NCT03860883
Protocol IDs
Treatment Sites (3)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
377.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
378.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
379.
381.
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05445778
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
382.
Mobile Health for Adherence in Breast Cancer Patients
Cancer Type
Breast Cancer
NCI ID
NCT06112613
Protocol IDs
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
383.
385.
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Cancer Type
Leukemia
NCI ID
NCT05224661
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
386.
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05568472
Protocol IDs
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
387.
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04762199
Protocol IDs
WINSHIP5153-20
NCI-2020-08392
388.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT03150914
Protocol IDs
Treatment Sites (1)
389.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type
Multiple Myeloma
NCI ID
NCT03732703
Protocol IDs
Treatment Sites (1)
392.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03779854
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
393.
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCI ID
NCT04314401
Protocol IDs
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
394.
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05091866
Protocol IDs
WINSHIP5184-20
NCI-2021-01498
STUDY00002155
395.
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type
Hematopoietic Malignancies, Melanoma
NCI ID
NCT03589339
Protocol IDs
Treatment Sites (1)
396.
Neuroblastoma Biology Study
Cancer Type
Neuroblastoma
NCI ID
NCT01587300
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
397.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT03983993
Protocol IDs
Treatment Sites (3)
398.
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type
Esophogeal Cancer
NCI ID
NCT03604991
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
399.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
400.
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03816345
Protocol IDs
Treatment Sites (1)
401.
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05664217
Protocol IDs
Treatment Sites (1)
403.
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04656496
Protocol IDs
Treatment Sites (1)
404.
Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03180268
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Piedmont Fayette Hospital
Fayetteville
404-851-2340
405.
Olanzapine versus Megestrol Acetate for the Treatment of Loss of Appetite among Advanced Cancer Patients
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04939090
Protocol IDs
A222004
A222004
A222004
NCI-2021-03303
406.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05580562
Protocol IDs
ONC201-108
NCI-2023-02479
408.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06016738
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
410.
411.
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05563220
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
412.
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients with Recurrent or Progressive Grade 2 or 3 Meningioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT02847559
Protocol IDs
Treatment Sites (1)
413.
414.
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04421222
Protocol IDs
Treatment Sites (1)
416.
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT04181060
Protocol IDs
Treatment Sites (1)
420.
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04049669
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
421.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT02343224
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
422.
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Cancer Type
Head and Neck Cancer
NCI ID
NCT03468218
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
423.
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04848337
Protocol IDs
HCRN GU19-385
NCI-2021-06868
425.
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05812807
Protocol IDs
Treatment Sites (3)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
428.
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer
NCI ID
NCT04815720
Protocol IDs
VX15/2503-12
NCI-2021-10364
KEYNOTE B84
429.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03690986
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
431.
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Cancer Type
Unknown Primary
NCI ID
NCT04731376
Protocol IDs
EU5097-20
NCI-2020-06998
432.
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Cancer Type
Leukemia
NCI ID
NCT04872478
Protocol IDs
2843-1003
NCI-2021-13604
433.
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type
Head and Neck Cancer, Sarcoma, Solid Tumor
NCI ID
NCT04541108
Protocol IDs
Treatment Sites (1)
434.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Sarcoma, Solid Tumor
NCI ID
NCT03715933
Protocol IDs
Treatment Sites (1)
435.
436.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03785249
Protocol IDs
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
437.
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03761108
Protocol IDs
Treatment Sites (1)
438.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT05098132
Protocol IDs
Treatment Sites (1)
440.
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
Cancer Type
Leukemia
NCI ID
NCT03960840
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
442.
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Cancer Type
Graft Versus Host Disease
NCI ID
NCT06046248
Protocol IDs
Treatment Sites (1)
443.
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT01311063
Protocol IDs
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
447.
Poly ICLC for the Treatment of Progressive or Recurrent Low-Grade Gliomas in Children and Young Adults with Neurofibromatosis Type 1
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT04544007
Protocol IDs
NF111
NCI-2022-03434
448.
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT04365374
Protocol IDs
GTM-102
NCI-2021-03480
449.
Predicting Childhood Cancer Survivors' Transition Readiness and Transfer Outcomes, SURV Transfer Outcomes Study
Cancer Type
Solid Tumor
NCI ID
NCT04257058
Protocol IDs
CHOA4312-18
NCI-2020-07495
450.
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT02402244
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
453.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCI ID
NCT01838512
Protocol IDs
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
455.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
456.
457.
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06074510
Protocol IDs
Treatment Sites (1)
459.
Radiation Therapy Alone, Radiation Therapy plus Leuprolide, or Radiation Therapy plus Relugolix for the Treatment of Non-metastatic Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT05320406
Protocol IDs
RAD5484-21
NCI-2022-00117
STUDY00003654
461.
Radiation Therapy with Protons or Photons in Treating Patients with Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT03186898
Protocol IDs
NRG-GI003
NRG-GI003
NCI-2016-02009
NRG-GI003
463.
Radiosurgery before Surgery for the Treatment of Brain Metastases
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04895592
Protocol IDs
RAD5234-21
NCI-2021-02761
STUDY00001896
464.
Reaching Rural Cancer Survivors Who Smoke
Cancer Type
Unknown Primary
NCI ID
NCT05008848
Protocol IDs
A211901
A211901
A211901
NCI-2021-03543
465.
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT06486454
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
466.
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT02724579
Protocol IDs
Treatment Sites (1)
467.
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation for the Treatment of Blood Cancer in Patients Undergoing Donor Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCI ID
NCT04191187
Protocol IDs
Treatment Sites (1)
468.
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04922307
Protocol IDs
VICCURO2114
NCI-2021-10595
471.
472.
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04427384
Protocol IDs
Treatment Sites (1)
473.
Registry Study for Radiation Therapy Outcomes
Cancer Type
Solid Tumor
NCI ID
NCT01255748
Protocol IDs
Treatment Sites (1)
474.
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCI ID
NCT05194293
Protocol IDs
Treatment Sites (1)
475.
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05257408
Protocol IDs
Treatment Sites (2)
476.
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT05998135
Protocol IDs
Treatment Sites (1)
478.
REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type
Sarcoma
NCI ID
NCT03838718
Protocol IDs
Treatment Sites (1)
479.
Rifaximin in Preventing Infections in Participants with Blood Cancer Undergoing Hematopoietic Stem Cell Transplantation
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT03529825
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
480.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03820817
Protocol IDs
Treatment Sites (1)
481.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03267433
Protocol IDs
Treatment Sites (1)
482.
Robotic vs. Open NSM for Early Stage Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05720039
Protocol IDs
Treatment Sites (1)
483.
Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT03610971
Protocol IDs
MCC-19660
NCI-2019-08022
HJKC3-0002
484.
S1400F Funding Placeholder
Cancer Type
NCI ID
Protocol IDs
S1400F
485.
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
Cancer Type
Lung Cancer, Solid Tumor
NCI ID
NCT06014658
Protocol IDs
Treatment Sites (1)
486.
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Cancer Type
Breast Cancer
NCI ID
NCT04650451
Protocol IDs
BPX603-201A
NCI-2021-00052
487.
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Cancer Type
Prostate Cancer
NCI ID
NCT02744287
Protocol IDs
BP-012
NCI-2019-02615
489.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Cancer Type
Leukemia
NCI ID
NCT03793478
Protocol IDs
AC220-A-U202
NCI-2019-02948
2016-002919-18
490.
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT03754933
Protocol IDs
PNP-002
NCI-2019-01328
14271
R01FD005746-01A1
492.
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
493.
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Cancer Type
Unknown Primary
NCI ID
NCT01656603
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
494.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCI ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
497.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06120491
Protocol IDs
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
498.
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT02636855
Protocol IDs
Treatment Sites (1)
499.
500.
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial
Cancer Type
Cervical Cancer
NCI ID
NCT06498661
Protocol IDs
Treatment Sites (1)
501.
Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05611931
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
503.
505.
Smoke-Free Homes Intervention for the Prevention of Smoking
Cancer Type
Unknown Primary
NCI ID
NCT04547686
Protocol IDs
SFH-5A-RCT
NCI-2021-01784
STUDY00001085
506.
Soccer-Based Lifestyle in Improving Bone and Metabolic Health in Prostate Cancer Survivors
Cancer Type
Prostate Cancer
NCI ID
NCT04144127
Protocol IDs
RSPH4684-19
NCI-2019-05183
IRB00110890
507.
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04185883
Protocol IDs
Treatment Sites (1)
508.
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients with Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT04908709
Protocol IDs
RAD4500-18
NCI-2018-02065
IRB00106849
509.
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Embryonal Tumors
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Neuroblastoma, Neurologocal Tumor
NCI ID
NCT02875314
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
514.
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04221542
Protocol IDs
Treatment Sites (1)
515.
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Cancer Type
Multiple Myeloma
NCI ID
NCT05396885
Protocol IDs
Treatment Sites (1)
516.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06267729
Protocol IDs
Treatment Sites (1)
517.
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT03013998
Protocol IDs
Treatment Sites (1)
518.
519.
520.
521.
Study of Chemotherapy, with or without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Cancer Type
Gallbladder Cancer
NCI ID
NCT05564403
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
522.
Study of CHS-114 in Participants With Advanced Solid Tumors
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCI ID
NCT05635643
Protocol IDs
Treatment Sites (1)
523.
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT05631574
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
524.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
525.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type
Leukemia
NCI ID
NCT04260022
Protocol IDs
Treatment Sites (1)
527.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05238922
Protocol IDs
Treatment Sites (1)
528.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04699188
Protocol IDs
CJDQ443A12101
NCI-2021-01594
529.
Study of Key Late-Occurring Complications in Childhood Cancer Survivors
Cancer Type
Multiple Primaries
NCI ID
NCT00082745
Protocol IDs
Treatment Sites (3)
530.
531.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Cancer Type
Cervical Cancer, Unknown Primary
NCI ID
NCT03108495
Protocol IDs
Treatment Sites (1)
532.
Study of Long-Term Follow-Up in Patients Who Have Participated in Children's Oncology Group Studies
Cancer Type
Multiple Primaries
NCI ID
NCT00736749
Protocol IDs
Treatment Sites (2)
533.
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05797831
Protocol IDs
KRT-232-118
NCI-2024-03038
ENGOT en-21
GOG-3089
534.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCI ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
535.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Cancer Type
Colon/Rectal Cancer, Gynecologic Cancers
NCI ID
NCT02628067
Protocol IDs
Treatment Sites (3)
536.
Study of PYX-106 in Solid Tumors
Cancer Type
Uterine Cancer
NCI ID
NCT05718557
Protocol IDs
Treatment Sites (1)
537.
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Cancer Type
Lung Cancer
NCI ID
NCT04310020
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
538.
Study of Renal Tumors in Pediatric Patients
Cancer Type
Kidney Cancer
NCI ID
NCT00898365
Protocol IDs
Treatment Sites (5)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
541.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCI ID
NCT05103345
Protocol IDs
Treatment Sites (1)
542.
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Cancer Type
Leukemia
NCI ID
NCT06073821
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
543.
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT06252649
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
545.
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04245397
Protocol IDs
Treatment Sites (1)
546.
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCI ID
NCT04947319
Protocol IDs
Treatment Sites (1)
547.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCI ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
548.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Cancer Type
Cervical Cancer, Unknown Primary
NCI ID
NCT06079671
Protocol IDs
Treatment Sites (1)
549.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05433142
Protocol IDs
Treatment Sites (1)
551.
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05067257
Protocol IDs
Treatment Sites (1)
552.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04879043
Protocol IDs
HDP-101-01
NCI-2021-04304
553.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCI ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
554.
556.
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05168566
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
557.
558.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
559.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05317416
Protocol IDs
Treatment Sites (1)
560.
Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05676931
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
561.
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT05602194
Protocol IDs
ACCL1931
ACCL1931
COG-ACCL1931
NCI-2022-08058
562.
563.
SurvivorLink in Improving Quality of Life in Cancer Survivors and Caregivers
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03543852
Protocol IDs
RSPH-AFLAC4297-18
NCI-2018-00396
IRB00101506
565.
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05910801
Protocol IDs
Treatment Sites (1)
566.
Talazoparib for the Treatment of BRCA 1/2 Mutant Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03990896
Protocol IDs
19-188
NCI-2019-07732
567.
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCI ID
NCT02693535
Protocol IDs
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
568.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCI ID
NCT05564377
Protocol IDs
EAY191
EAY191
NCI-2022-06842
569.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCI ID
NCT03155620
Protocol IDs
Treatment Sites (1)
572.
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type
Breast Cancer
NCI ID
NCT04457596
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
573.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCI ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
575.
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05976763
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
576.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Cancer Type
Ovarian Cancer, Uterine Cancer
NCI ID
NCT05950464
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
578.
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05633615
Protocol IDs
Treatment Sites (1)
579.
580.
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT03811015
Protocol IDs
Treatment Sites (5)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
581.
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05112601
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
582.
583.
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCI ID
NCT05432791
Protocol IDs
Treatment Sites (1)
585.
Testing Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases
Cancer Type
Breast Cancer
NCI ID
NCT04647916
Protocol IDs
S2007
S2007
NCI-2020-07706
586.
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases.
Cancer Type
Brain Tumor, Breast Cancer
NCI ID
NCT04647916
Protocol IDs
S2007
NCI-2020-07706
588.
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT03126916
Protocol IDs
Treatment Sites (1)
589.
Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type
Breast Cancer
NCI ID
NCT03418961
Protocol IDs
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
591.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type
Lung Cancer
NCI ID
NCT04267848
Protocol IDs
Treatment Sites (19)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
593.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
595.
Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05879926
Protocol IDs
Treatment Sites (4)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
597.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04803201
Protocol IDs
598.
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT05624996
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
599.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05276973
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
600.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
602.
Testing the Addition of Nivolumab to Standard Treatment for Patients with Metastatic or Unresectable Colorectal Cancer that have a BRAF Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05308446
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
603.
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type
Lung Cancer
NCI ID
NCT04929041
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
604.
605.
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment with the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05538897
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
608.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04134260
Protocol IDs
NRG-GU008
NRG-GU008
NCI-2019-06838
609.
611.
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05673148
Protocol IDs
Treatment Sites (1)
613.
Testing the Anti-Cancer Drug Darolutamide in Patients with Testosterone-driven Salivary Gland Cancers
Cancer Type
Head and Neck Cancer
NCI ID
NCT05669664
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
615.
616.
617.
Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and/or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT04201457
Protocol IDs
PBTC-055
PBTC-055
NCI-2019-06216
621.
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05710406
Protocol IDs
Treatment Sites (3)
622.
Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCI ID
NCT05040360
Protocol IDs
Treatment Sites (3)
624.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04530565
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
626.
Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer
Cancer Type
Pancreatic Cancer
NCI ID
NCT04340141
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
627.
Testing the Usual Treatment of Radiation Therapy and HER2-Targeted Therapy to HER2-Targeted Therapy Alone for Low-Risk HER2-Positive Breast Cancer, The HERO Trial
Cancer Type
Breast Cancer
NCI ID
NCT05705401
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
628.
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04852887
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
630.
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04155034
Protocol IDs
Treatment Sites (4)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
631.
633.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCI ID
NCT03805789
Protocol IDs
Treatment Sites (1)
634.
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04768868
Protocol IDs
IMP7068 - 101
NCI-2021-13607
635.
636.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
637.
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT05235165
Protocol IDs
AOST2031
AOST2031
NCI-2021-14237
638.
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Kidney Cancer, Sarcoma, Solid Tumor
NCI ID
NCT05286801
Protocol IDs
PEPN2121
PEPN2121
NCI-2022-01992
639.
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02775383
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
640.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Cancer Type
Lung Cancer
NCI ID
NCT05468489
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
641.
Tolinapant and Radiation Therapy for the Treatment of Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT05245682
Protocol IDs
WINSHIP5380-21
NCI-2021-09678
STUDY00002992
643.
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT04616560
Protocol IDs
PEPN1924
NCI-2020-08428
PEPN1924
644.
Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD
Cancer Type
Unknown Primary
NCI ID
NCT05090384
Protocol IDs
Treatment Sites (1)
645.
Treosulfan-Based Conditioning Regimen before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04965597
Protocol IDs
RG1121820
NCI-2021-13862
BMT CTN 1904
646.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02495415
Protocol IDs
Treatment Sites (1)
647.
Tumor Treating Fields for the Treatment of Brainstem Gliomas
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05310448
Protocol IDs
Treatment Sites (1)
650.
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type
Quality of Life
NCI ID
Protocol IDs
Treatment Sites (4)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
652.
Use of Lymphatic Mapping to Guide Radiotherapy to the Neck in Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT05451004
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
654.
Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05174169
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
656.
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05183035
Protocol IDs
ITCC-101/APAL2020D
NCI-2022-07200
2021-003212-11
658.
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT04847453
Protocol IDs
Treatment Sites (1)
659.
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04590664
Protocol IDs
WINSHIP5070-20
NCI-2020-05187
660.
VGX-3100 and Electroporation in Treating Patients with HIV-Positive High-Grade Anal Lesions
Cancer Type
Anal Cancer, Unknown Primary
NCI ID
NCT03603808
Protocol IDs
AMC-103
AMC-103
NCI-2017-01740
661.
663.
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT02523014
Protocol IDs
Treatment Sites (2)
664.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCI ID
NCT03842696
Protocol IDs
Treatment Sites (1)
665.
Vudalimab in Combination with Standard of Care Treatment in Patients with Metastatic Castration Sensitive Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05733351
Protocol IDs
Treatment Sites (2)
666.
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents with Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03223753
Protocol IDs
Treatment Sites (1)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
667.
WP1066 for the Treatment of Recurrent or Refractory and Progressive Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04334863
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
668.
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT05678998
Protocol IDs
Treatment Sites (1)